Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
Study met primary and secondary endpoints Paridiprubart demonstrated a relative reduction in the risk of death of 25% Treatment provided patients with clinically meaningful improvement in survival and recovery Paridiprubart exhibited consistent safety and tol
(Financial Post, 2025-10-28T11:45:08Z)